Skip to main content

Sektorenübergreifende interdisziplinäre Zusammenarbeit der Arbeitsgemeinschaft Internistische Onkologie in der Präzisionsonkologie

Cross-sectoral interdisciplinary collaboration of the Arbeitgemeinschaft Internistische Onkologie (AIO) in precision oncology

This is a preview of subscription content, access via your institution.

Abb. 1


  1. Aga (2011) American gastroenterological association medical position statement on the management of Barrett’s esophagus. Gastroenterology 140:1084–1091

    Article  Google Scholar 

  2. Barlesi F, Drilon A, De Braud F et al (2019) Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK‑1 and STARTRK‑2. Ann Oncol 30:ii48–ii49

    Article  Google Scholar 

  3. Bedard PL, Hyman DM, Davids MS et al (2020) Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395:1078–1088

    CAS  Article  Google Scholar 

  4. Coleman HG, Bhat S, Murray LJ et al (2011) Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidemiol 26:739–745

    Article  Google Scholar 

  5. Corley DA, Kubo A, Levin TR et al (2009) Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994–2006. Gut 58:182–188

    CAS  Article  Google Scholar 

  6. Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion—positive cancers in adults and children. N Engl J Med 378:731–739

    CAS  Article  Google Scholar 

  7. Falk GW (2002) Barrett’s esophagus. Gastroenterology 122:1569–1591

    Article  Google Scholar 

  8. Horak P, Heining C, Kreutzfeldt S et al (2021) Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov 11(11):2780–2795.

  9. Horak P, Klink B, Heining C et al (2017) Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer 141:877–886

    CAS  Article  Google Scholar 

  10. Kreutzfeldt S, Apostolidis L, Oles M et al (2019) Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: updated results from the German NCT/DKTK MASTER trial. Ann Oncol 30:vii6

    Article  Google Scholar 

  11. Larson KL, Huang B, Weiss HL et al (2021) Clinical outcomes of molecular tumor boards: a systematic review. JCO Precis Oncol 9(5):PO.20.00495.

    Article  Google Scholar 

  12. Leichsenring J, Horak P, Kreutzfeldt S et al (2019) Variant classification in precision oncology. Int J Cancer 145:2996–3010

    CAS  Article  Google Scholar 

  13. Marabelle A, Le DT, Ascierto PA et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38:1–10

    CAS  Article  Google Scholar 

  14. MD Anderson Cancer Center Institute for Personalized Cancer Therapy.

  15. Moscow JA, Fojo T, Schilsky RL (2018) The evidence framework for precision cancer medicine. Nat Rev Clin Oncol 15:183–192

    Article  Google Scholar 

  16. Quante M (2020) BarrettNET – Risikoevaluation und Prävention von Adenokarzinomen des Ösophagus. In: Forum. Springer, Berlin Heidelberg, S 342–344

    Google Scholar 

  17. Quante M, Bhagat G, Abrams JA et al (2012) Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 21(1):36–51.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. Schmidt M, Ankerst DP, Chen Y et al (2020) Epidemiological risk factors in a comparison of a Barrett Esophagus Registry (BarretNET) and a case control population in Germany. Cancer Prev Res 13(4):377–384.

    Article  Google Scholar 

  19. Stenzinger A, Van Tilburg CM, Tabatabai G et al (2021) Diagnosis and therapy of tumors with NTRK gene fusion. Pathologe 42:103–115

    Article  Google Scholar 

  20. Wani S, Falk GW, Post J et al (2011) Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology 141:1179–1186, 1186.e1

    Article  Google Scholar 

  21. Westphalen BC, Bokemeyer C, Büttner R et al (2020) Conceptual framework for precision cancer medicine in Germany: consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy. Eur J Cancer 135:1–7

    Article  Google Scholar 

  22. Wiethaler M, Slotta-Huspenina J, Brandtner A et al (2019) BarrettNET—a prospective registry for risk estimation of patients with Barrett’s esophagus to progress to adenocarcinoma. Dis Esophagus 32(8):doz024.

    Article  PubMed  Google Scholar 

  23. Annals of Oncology (2021) 32 (suppl_5):S530–S582.

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Sonja Loges.

Ethics declarations


C.-B. Westphalen, M. Quante, B. Söhlke, M. Wartenberg, W. Knauf, T. Illmer, E. Gökkurt, A. Tannapfel, F. Griesinger, A. Reinacher-Schick und S. Loges geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Westphalen, CB., Quante, M., Söhlke, B. et al. Sektorenübergreifende interdisziplinäre Zusammenarbeit der Arbeitsgemeinschaft Internistische Onkologie in der Präzisionsonkologie. Onkologe 28 (Suppl 1), 6–16 (2022).

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: